Portal de Periódicos da CAPES

Trends and Patterns of Testosterone Therapy among U.S. Male Medicare Beneficiaries, 1999 to 2014

2020; Lippincott Williams & Wilkins; Volume: 203; Issue: 6 Linguagem: Inglês

10.1097/ju.0000000000000744

1527-3792

Cindy Ke Zhou, Shailesh Advani, Matthew Chaloux, James T. Gibson, Mandi Yu, Marie C. Bradley, Robert N. Hoover, Michael B. Cook,

Genetic and Clinical Aspects of Sex Determination and Chromosomal Abnormalities

No AccessJournal of UrologyAdult Urology1 Jun 2020Trends and Patterns of Testosterone Therapy among U.S. Male Medicare Beneficiaries, 1999 to 2014 Cindy Ke Zhou, Shailesh Advani, Matthew Chaloux, James Todd Gibson, Mandi Yu, Marie Bradley, Robert N. Hoover, and Michael B. Cook Cindy Ke ZhouCindy Ke Zhou *Correspondence: Metabolic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, 9609 Medical Center Drive, Bethesda, Maryland 20892 E-mail Address: [email protected] Metabolic Epidemiology Branch, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland , Shailesh AdvaniShailesh Advani Social Epidemiology Research Unit, Social Behavioral Research Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland , Matthew ChalouxMatthew Chaloux Division of Cancer Epidemiology and Genetics, Surveillance Research Program, National Cancer Institute, Bethesda, Maryland , James Todd GibsonJames Todd Gibson Information Management Services, Inc., Rockville, Maryland , Mandi YuMandi Yu Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland , Marie BradleyMarie Bradley Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland , Robert N. HooverRobert N. Hoover Epidemiology and Biostatics Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland , and Michael B. CookMichael B. Cook *Correspondence: Metabolic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, 9609 Medical Center Drive, Bethesda, Maryland 20892 E-mail Address: [email protected] Metabolic Epidemiology Branch, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland View All Author Informationhttps://doi.org/10.1097/JU.0000000000000744AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We explored the Medicare database (1999 to 2014) to provide a comprehensive assessment of testosterone therapy patterns in the older U.S. male population. Materials and Methods: We estimated annual age-standardized incidence (new users) and prevalence (existing users) of testosterone therapy according to demographic characteristics, comorbidities and potential indications. Results: There were 392,698 incident testosterone therapy users during 88 million person-years. Testosterone therapy users were predominantly younger, white nonHispanic, and located in South and West U.S. Census regions. On average testosterone therapy use increased dramatically during 2007 to 2014 (average annual percent change 15.5%), despite a decrease in 2014. In 2014 the most common recorded potential indications for any testosterone therapy were hypogonadism (48%), fatigue (18%), erectile dysfunction (15%), depression (4%) and psychosexual dysfunction (1%). Laboratory tests to measure circulating testosterone concentrations for testosterone therapy were infrequent with 35% having had at least 1 testosterone test in the 120 days preceding testosterone therapy, 4% the recommended 2 pre-testosterone therapy tests, and 16% at least 1 pre-testosterone therapy test and at least 1 post-testosterone therapy test. Conclusions: Testosterone therapy remains common in the older U.S. male population, despite a recent decrease. Although testosterone therapy prescriptions are predominantly for hypogonadism, a substantial proportion appear to be for less specific conditions. Testosterone tests among men prescribed testosterone therapy appear to be infrequent. References 1. : Endogenous and exogenous testosterone and prostate cancer: decreased-, increased- or null-risk?Transl Androl Urol 2017; 6: 566. Google Scholar 2. : Relationship between low levels of anabolic hormones and 6-year mortality in older men: the aging in the Chianti Area (InCHIANTI) study. Arch Intern Med 2007; 167: 2249. Google Scholar 3. : Endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2011; 96: 3007. Google Scholar 4. : Testosterone deficiency. Am J Med 2011; 124: 578. Google Scholar 5. : Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001; 86: 724. Google Scholar 6. : Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J Clin Endocrinol Metab 2008; 93: 2737. Google Scholar 7. : Hypogonadism: its prevalence and diagnosis. Urol Clin North Am 2016; 43: 163. Google Scholar 8. : Endocrinology of the aging male. Best Pract Res Clin Endocrinol Metab 2011; 25: 303. Google Scholar 9. : Global trends in testosterone prescribing, 2000-2011: expanding the spectrum of prescription drug misuse. Med J Aust 2013; 199: 548. Google Scholar 10. : Association between direct-to-consumer advertising and testosterone testing and initiation in the United States, 2009-2013. JAMA 2017; 317: 1159. Google Scholar 11. : Marketing and testosterone treatment in the USA: a systematic review. Eur Urol Focus 2017; 3: 395. Google Scholar 12. : Trends in testosterone replacement therapy use from 2003 to 2013 among reproductive-age men in the United States. J Urol 2017; 197: 1121. Link, Google Scholar 13. : Trends in androgen prescribing in the United States, 2001 to 2011. JAMA Intern Med 2013; 173: 1465. Google Scholar 14. : Using a composite index of socioeconomic status to investigate health disparities while protecting the confidentiality of cancer registry data. Cancer Causes Control 2014; 25: 81. Google Scholar 15. : Socioeconomic status and breast cancer incidence in California for different race/ethnic groups. Cancer Causes Control 2001; 12: 703. Google Scholar 16. : Development of a comorbidity index using physician claims data. J Clin Epidemiol 2000; 53: 1258. Google Scholar 17. : Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 2000; 19: 335. Google Scholar 18. R Core Team: R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2017. Available at https://www.R-project.org/. Google Scholar 19. : Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2006; 91: 1995. Google Scholar 20. : Testosterone lab testing and initiation in the United Kingdom and the United States, 2000 to 2011. J Clin Endocrinol Metab 2014; 99: 835. Google Scholar 21. : Testosterone prescribing in the United States, 2002-2016. JAMA 2018; 320: 200. Google Scholar 22. : The impact of drug reimbursement policy on rates of testosterone replacement therapy among older men. PLoS One 2014; 9: e98003. Google Scholar 23. : Testosterone therapy in the new era of Food and Drug Administration oversight. Transl Androl Urol 2016; 5: 207. Google Scholar 24. : Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2018; 103: 1715. Google Scholar 25. : Use of hormone testing for the diagnosis and evaluation of male hypogonadism and monitoring of testosterone therapy: application of hormone testing guideline recommendations in clinical practice. J Sex Med 2015; 12: 1886. Google Scholar Supported by the Sallie Rosen Kaplan Fellowship for Women Scientists (CKZ) and the Intramural Program of the Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health. No direct or indirect commercial, personal, academic, political, religious or ethical incentive is associated with publishing this article. © 2020 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited bySeftel A (2020) Re: Treatment of Male Hypogonadism Partially Reverses Oxidative Stress in Patients with HypogonadismJournal of Urology, VOL. 204, NO. 6, (1363-1363), Online publication date: 1-Dec-2020.Seftel A (2020) Re: Erectile Dysfunction and Cardiovascular Risk: A Review of Current FindingsJournal of Urology, VOL. 204, NO. 3, (601-601), Online publication date: 1-Sep-2020.Smith J (2020) This Month in Adult UrologyJournal of Urology, VOL. 203, NO. 6, (1033-1034), Online publication date: 1-Jun-2020. Volume 203Issue 6June 2020Page: 1184-1190Supplementary Materials Advertisement Copyright & Permissions© 2020 by American Urological Association Education and Research, Inc.KeywordshypogonadismMedicaretrendstestosteroneepidemiologyAcknowledgmentsRuth Parsons and Winnie Ricker at Information Management Services, Inc. shared their expertise in Medicare data, and Dr. Barry I. Graubard of the Biostatistics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, provided statistical expertise and input.MetricsAuthor Information Cindy Ke Zhou Metabolic Epidemiology Branch, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland *Correspondence: Metabolic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, 9609 Medical Center Drive, Bethesda, Maryland 20892 E-mail Address: [email protected] Equal study contribution. More articles by this author Shailesh Advani Social Epidemiology Research Unit, Social Behavioral Research Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland Equal study contribution. More articles by this author Matthew Chaloux Division of Cancer Epidemiology and Genetics, Surveillance Research Program, National Cancer Institute, Bethesda, Maryland More articles by this author James Todd Gibson Information Management Services, Inc., Rockville, Maryland More articles by this author Mandi Yu Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland More articles by this author Marie Bradley Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland More articles by this author Robert N. Hoover Epidemiology and Biostatics Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland More articles by this author Michael B. Cook Metabolic Epidemiology Branch, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland *Correspondence: Metabolic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, 9609 Medical Center Drive, Bethesda, Maryland 20892 E-mail Address: [email protected] More articles by this author Expand All Supported by the Sallie Rosen Kaplan Fellowship for Women Scientists (CKZ) and the Intramural Program of the Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health. No direct or indirect commercial, personal, academic, political, religious or ethical incentive is associated with publishing this article. Advertisement PDF downloadLoading ...